Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 04 December, 2019

Northern Trust Corp

Form 8.3 - ALLERGAN PLC

RNS Number : 7079V
Northern Trust Corporation
04 December 2019
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

 Northern Trust Corporation

Company dealt in

 Allergan PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

 Common Stock USD 0.0033

of dealing

 3rd  December 2019

 

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

 

 

 

(1) Relevant securities

 3,861,306    1.18% *

 

Derivatives than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 3,861,306    1.18% *

 

             

 

* Note: The difference in holdings from yesterday and today not explained by transactions, can be explained by stock transfers of 70 securities into the relevant accounts.

 

 

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

 

 

(1) Relevant securities

 

 

 

Derivatives than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit ($)

SELL

643

185.24

BUY

7

185.09

SELL

62

185.09

SELL

138

185.09

SELL

522

185.09

BUY

40

185.12

BUY

2

185.3

BUY

45

185.03

BUY

4

185.09

BUY

3

185.09

BUY

96

185.09

BUY

6

185.09

BUY

5

185.09

BUY

7

185.12

SELL

3

185.09

BUY

9

185.09

SELL

57

185.43

SELL

200

185.191

SELL

1

185.3

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

CFD

Nature of transaction

6)

Number of relevant securities

7)

Price per unit

5)

 

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

of transaction

8)

per unit

 

 

 

 

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Date of disclosure

 04th December 2019

Contact name

 Luke Piscina

Telephone number

 0207 982 3697

If a connected EFM, name of offeree/offeror with which connected

 

 

If a connected EFM, state nature of connection (Note 10)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFSSFILFUSEEE

a d v e r t i s e m e n t